Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187214 | 0.98 | CYP4F2 (0.51) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL5705263 | 0.92 | CYP4F2 (0.47) | CYP4F2CYP4A11P4HB | |
| SCHEMBL797984 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL798199 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL798227 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL798441 | 0.91 | CYP4F2 (0.60) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL25996655 | 0.86 | CYP4F2 (0.68) | CYP4F2CYP4A11TDP1P4HBDGAT1 | |
| SCHEMBL187373 | 0.84 | CYP4F2 (0.51) | CYP4F2CYP4A11MAPTKMT2A | |
| SCHEMBL14892163 | 0.84 | CYP4F2 (0.65) | CYP4F2CYP4A11TDP1P4HBDGAT1 | |
| SCHEMBL23971374 | 0.83 | CYP4F2 (0.53) | CYP4F2CYP4A11TDP1EPHX2P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695266-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213143-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024212248-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-1701931-B1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9452964-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | ESPERION THERAPEUTIC, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885HDAC1 3294/4885 |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | PNLIP, APOL1, NR1H3 | CYP4F2 2326/4885CYP4A11 145/4885HDAC1 3679/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HDAC1 1479/4885 |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HDAC1 1479/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885HDAC1 3294/4885 |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PNLIP, CYP27A1, GPR119 | CYP4F2 1797/4885CYP4A11 70/4885HDAC1 4094/4885 |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885HDAC1 3294/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885HDAC1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.